Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

• DOI: 10.1128/spectrum.01390-22
• Publication Date: 2022-08-16T13:03:53Z
• Authors: Congjuan Xu; Xiaoya Wei; Yongxin Jin; Fang Bai; Zhihui Cheng; Shuiping Chen; Xiaolei Pan; Weihui Wu
• Keywords: Proteomics; 0301 basic medicine; Protease La; lon; Porins; Drug Collateral Sensitivity; Microbial Sensitivity Tests; Microbiology; collateral sensitivity; beta-Lactamases; eravacycline; Mice; Aztreonam; 03 medical and health sciences; Animals; QR1-502; Anti-Bacterial Agents; Klebsiella Infections; 3. Good health; Klebsiella pneumoniae; Carbapenems; Tetracyclines; beta-Lactamase Inhibitors; Azabicyclo Compounds; Research Article

The increasing bacterial antibiotic resistance is a serious threat to global public health, which demands novel antimicrobial medicines and treatment strategies. Eravacycline is a newly approved antibiotic that belongs to the tetracycline antibiotics.